On November 28, 2023, Ensysce Biosciences, Inc. closed the transaction. The company announced that it has issued senior secured convertible promissory notes in the aggregate principal amount of $1,224,000 for an aggregate purchase price of $1,133,333 in its second and final tranche closing. The company issued warrants to purchase 2,511,394 shares.